TLR7 Agonist Solid Composition for Stable Direct Compression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a suitable pharmaceutical composition comprising a Toll-like receptor 7 (TLR7) agonist to effectively treat or prevent viral infections, particularly hepatitis B and hepatitis C, while minimizing side effects associated with excessive cytokine secretion.
Innovation Solution
A solid pharmaceutical composition comprising a TLR7 agonist compound, specifically 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine, is formulated with a diluent, binder, and lubricant using a direct compression method, without milling, to ensure homogeneity, stability, and dissolution properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a TLR7 agonist is used to treat viral infections, then antiviral efficacy is improved, but excessive cytokine secretion causes serious side effects
Solution Approach 1:
The patent modifies the chemical structure of TLR7 agonists by introducing specific substituents (R1-R6 groups) to optimize the balance between antiviral activity and cytokine secretion control. By changing molecular parameters such as adding hydrophobic groups at specific positions, the drug achieves selective activation of TLR7 with reduced off-target effects and controlled cytokine response.
2Reliability
If a solid pharmaceutical composition is formulated with multiple excipients, then stability and dissolution properties are improved, but manufacturing complexity increases
Solution Approach 1:
The patent specifies pre-determined ratios and selection criteria for excipients (diluent, binder, disintegrant, lubricant) that can be directly combined with the TLR7 agonist without requiring complex intermediate processing steps. The direct compression method is enabled by preliminary optimization of particle size and surface properties of both active ingredient and excipients, allowing straightforward manufacturing.
3Stability of the object's composition
If milling is performed during preparation, then homogeneity is improved, but drug stability may deteriorate
Solution Approach 1:
The patent employs preliminary size reduction and surface treatment of the TLR7 agonist before formulation, creating particles with optimized characteristics that can be directly compressed. This pre-processing ensures uniform distribution and adequate flow properties without requiring intensive milling during manufacturing, thereby maintaining drug stability while achieving homogeneity.
Data Source
AI summary
A solid pharmaceutical composition comprising a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine, a preparation method therefor, and an medical application thereof. The solid pharmaceutical composition has excellent stability and dissolution properties.